0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Inhibitors of Cholesterol Synthesis and Cataracts

Richard J. Cenedella, PhD
JAMA. 1987;257(12):1602. doi:10.1001/jama.1987.03390120064020.
Text Size: A A A
Published online

To the Editor.—  The results presented in the article entitled "Therapeutic Response to Lovastatin (Mevinolin) in Nonfamilial Hypercholoesterolemia"1 clearly indicate that lovastatin (a potent inhibitor of the rate-limiting step in cholesterol biosynthesis) could be a useful agent for the management of an elevated low-density lipoprotein cholesterol level. The purpose of this letter is to caution against the possible complication of cataract development that might result from long-term use of this agent. Although the authors reported no apparent increases in lens opacities in adult subjects treated for 18 weeks with lovastatin, they should be aware that serious consequences could result from long-term inhibition of cholesterol synthesis by the ocular lens, especially in children and young adults.The avascular lens grows throughout life by laying down layer upon layer of permanently retained fiber cells that are enclosed by an extremely cholesterol-rich plasma membrane. The human lens increases in size with each

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();